Home / Resource Library / MORNINGSUN: OPEN-LABEL PHASE II TRIAL OF THE EFFICACY AND SAFETY OF SUBCUTANEOUS MOSUNETUZUMAB (MOSUN SC) AS FRONTLINE (1L) TREATMENT IN SYMPTOMATIC PATIENTS WITH MARGINAL ZONE LYMPHOMA (MZL)

MORNINGSUN: OPEN-LABEL PHASE II TRIAL OF THE EFFICACY AND SAFETY OF SUBCUTANEOUS MOSUNETUZUMAB (MOSUN SC) AS FRONTLINE (1L) TREATMENT IN SYMPTOMATIC PATIENTS WITH MARGINAL ZONE LYMPHOMA (MZL)

EHA 2025

Membership Organisation

Healthcare Professional

Affected by Lymphoma

Researcher or Advocate

MORNINGSUN: OPEN-LABEL PHASE II TRIAL OF THE EFFICACY AND SAFETY OF SUBCUTANEOUS MOSUNETUZUMAB (MOSUN SC) AS FRONTLINE (1L) TREATMENT IN SYMPTOMATIC PATIENTS WITH MARGINAL ZONE LYMPHOMA (MZL)